Literature DB >> 12084502

Determination of lipophilicity of two quinolone antibacterials, ciprofloxacin and grepafloxacin, in the protonation equilibrium.

Jin Sun1, Shigeko Sakai, Yoshihiko Tauchi, Yoshiharu Deguchi, Jimin Chen, Ruhua Zhang, Kazuhiro Morimoto.   

Abstract

The objective of this study was to compare protonation equilibrium and lipophilicity of two quinolone antibacterials, grepafloxacin (GPFX) and ciprofloxacin (CPFX), in order to give an insight into effects on the physicochemical properties by slight structural motifs. The protonation equilibrium was investigated by a spectrophotometry. Macro- and micro-dissociation constants were simultaneously determined, based on nonlinear regression analysis using the MULTI program, and then microspecies distribution could be described accordingly. Zwitterionic microspecies predominated at isoelectrical point (pI) for both drugs, and the concentration ratio of neutral to zwitterionic forms was near 4-fold greater for GPFX than that for CPFX. The apparent partition coefficient (D(O/B,pH)) versus pH profiles had the shape of a parabolic curve in an n-octanol/buffer system, and reached the maximum around pI for both, respectively. Moreover, two introduced methyl groups in GPFX increased not only intrinsic lipophilicity but also neutral microspecies fraction relative to CPFX, and D(O/B,pH) of GPFX was consequently far higher than that of CPFX. The results emphasized that there were significant differences in protonation equilibrium and lipophilicity between GPFX and CPFX, which conduced to explaining their different behavior in terms of antibacterial activities and pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084502     DOI: 10.1016/s0939-6411(02)00018-8

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Polymorphism and intramolecular proton transfer in fluoroquinolone compounds.

Authors:  Anna V Polishchuk; Emilya T Karaseva; Tatyna B Emelina; Oana Cramariuc; Vladimir E Karasev
Journal:  J Fluoresc       Date:  2011-07-13       Impact factor: 2.217

2.  Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.

Authors:  E Kłosińska-Szmurło; F A Pluciński; M Grudzień; K Betlejewska-Kielak; J Biernacka; A P Mazurek
Journal:  J Biol Phys       Date:  2014-07-18       Impact factor: 1.365

3.  Characterization of the interactions between fluoroquinolone antibiotics and lipids: a multitechnique approach.

Authors:  Hayet Bensikaddour; Nathalie Fa; Ingrid Burton; Magali Deleu; Laurence Lins; André Schanck; Robert Brasseur; Yves F Dufrêne; Erik Goormaghtigh; Marie-Paule Mingeot-Leclercq
Journal:  Biophys J       Date:  2008-01-04       Impact factor: 4.033

4.  A simple way for targeted delivery of an antibiotic: In vitro evaluation of a nanoclay-based composite.

Authors:  Leslie Valdés; Irela Pérez; Louis Charles de Ménorval; Ernesto Altshuler; Jon Otto Fossum; Aramis Rivera
Journal:  PLoS One       Date:  2017-11-17       Impact factor: 3.240

5.  The effect of some fluoroquinolone family members on biospeciation of copper(II), nickel(II) and zinc(II) ions in human plasma.

Authors:  Predrag Djurdjevic; Ivan Jakovljevic; Ljubinka Joksovic; Nevena Ivanovic; Milena Jelikic-Stankov
Journal:  Molecules       Date:  2014-08-13       Impact factor: 4.411

6.  Fluoroquinolone Metalloantibiotics to Bypass Antimicrobial Resistance Mechanisms: Decreased Permeation through Porins.

Authors:  Mariana Ferreira; Carla F Sousa; Paula Gameiro
Journal:  Membranes (Basel)       Date:  2020-12-22

7.  Ciprofloxacin salt and salt co-crystal with di-hydroxy-benzoic acids.

Authors:  Yuda Prasetya Nugraha; Haruki Sugiyama; Hidehiro Uekusa
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2022-02-03

8.  Alkalising agents in urinary tract infections: theoretical contraindications, interactions and synergy.

Authors:  Oisín N Kavanagh
Journal:  Ther Adv Drug Saf       Date:  2022-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.